Product logins

Find logins to all Clarivate products below.


Biosimilars | Target Product Profile Simulator | Oncology | 2020

Related Market Assessment Reports

Report
Oncology Brand Tracker – Immune Checkpoint Inhibitors | 2020
Driven by DRG’s oncology expertise and real-world data capabilities, the Real World Brand Tracker is an interactive dashboard of regularly updated U.S. claims data that monitors and highlights…
Report
Biosimilars – Geographic Focus: China – Biosimilars – China In-Depth (China)
China’s biosimilar market has transformed significantly since February 2019, following the approval of Shanghai Henlius Biotech’s HLX01—a biosimilar of Roche’s MabThera (rituximab). The…
Report
Biosimilars – Emerging Biosimilars – Emerging Biosimilars Landscape
The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 735 currently available and novel biosimilar products, detailing…
Report
Biosimilars – Current Treatment – Endocrinology
Eli Lilly / Boehringer Ingelheim’s Abasaglar / Basaglar was the first biosimilar / follow-on insulin glargine to launch in Europe and the United States, followed by Sanofi’s Admelog / Insulin…
Report
Biosimilars – Current Treatment – Ophthalmology
The ophthalmology market is relatively new in the field of biosimilars: Samsung Bioepis / Biogen’s ranibizumab biosimilar, Byooviz, was the first MAb biosimilar to launch in the U.S. market in…